Pain

"Keeping New Jersey Youth Athletes Safe": Addressing the Opioid Epidemic in Youth Sports

Retrieved on: 
Thursday, March 14, 2024
Research, Prohibition, Organization, Sport, Communication, Partnership, Knowledge, Heller, FREE, Athlete, Monmouth University, Advertising, Social policy, Rutgers University, Pain, Georgian Court University, NFL, Government

The conference, “Keeping New Jersey Youth Athletes Safe,” will be held from 10 a.m. to 3 p.m. Friday, April 19, at the Golden Nugget Hotel & Casino in Atlantic City.

Key Points: 
  • The conference, “Keeping New Jersey Youth Athletes Safe,” will be held from 10 a.m. to 3 p.m. Friday, April 19, at the Golden Nugget Hotel & Casino in Atlantic City.
  • The event, being held in conjunction with Horizon Blue Cross Blue Shield of New Jersey and the Opioid Education Foundation of America, will be tailored for coaches, athletic directors, athletic trainers, and others involved in youth sports.
  • “It’s essential to educate those involved in youth sports about the potential for opioid misuse among student-athletes,” said Angelo Valente, Executive Director of PDFNJ.
  • Kolodny, also the executive director of Physicians for Responsible Opioid Prescribing, will discuss the opioid epidemic that is impacting families and communities across the country.

Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Retrieved on: 
Thursday, March 14, 2024
Principal, Ethanol, Collateral damage, Disease, Nervous system, Patient, POC, Pancreatic cancer, Clinical trial, Pain, AMIX, Medical imaging

THE WOODLANDS, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the safe completion of the first three patient procedures for its proof-of-concept (PoC) human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • “We are pleased to have safely completed the first patient procedures utilizing RF ablation in a transvascular approach to reduce the pain associated with pancreatic cancer.
  • The Principal Investigator was able to navigate the catheter to the target treatment area and perform the specified ablations with no significant adverse events.
  • The primary objective of the PoC human clinical trial is to successfully ablate relevant somatic nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Retrieved on: 
Wednesday, March 13, 2024
Knee, Congress, Biologics license application, Patient, ATMP, Research, World Congress, OARSI, European Medicines Agency, WOMAC, Osteoarthritis Research Society International, KOOS, Drug development, Safety, Pain, Vasopressin receptor 2, DVD-Audio, Food, Osteoarthritis, FDA, BLA, Pharmaceutical industry

TAMPA, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 (enekinragene inzadenovec), the company’s novel, intra-articular helper-dependent adenovirus (HDAd) gene therapy product candidate that codes for interleukin-1 receptor antagonist (IL-1Ra), for the treatment of osteoarthritis of the knee.

Key Points: 
  • PCRX-201 was well tolerated, with efficacy observed through at least 52 weeks at all doses and cohorts.
  • Preliminary 36-week data were presented at the Osteoarthritis Research Society International (OARSI) 2023 World Congress, the premier annual international forum in osteoarthritis research and treatment.
  • The 52-week data have been accepted for presentation at OARSI 2024 taking place in Vienna, Austria in April 2024 and the company expects to present 104-week efficacy and safety data later this year.
  • PCRX-201 was also granted Advanced Therapy Medicinal Products (ATMP) designation by the European Medicines Agency in May 2023.

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

Retrieved on: 
Wednesday, March 13, 2024
TENS, Fibromyalgia, Label, Patient, Contraindication, Sleep, Sale, Rehabilitation, Physical medicine and rehabilitation, Consultant, Pain

WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022.

Key Points: 
  • WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022.
  • “We have been pleased by the positive response to Quell Fibromyalgia from providers taking care of patients with fibromyalgia during our strategic launch phase,” said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix.
  • In my practice, we have even had some patients report they were able to reduce pain with Quell Fibromyalgia that medications have never helped before."
  • The sale, distribution, and use of Quell Fibromyalgia is restricted to prescription use in accordance with 21 CFR 801.109.

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

Retrieved on: 
Wednesday, March 13, 2024
Clobetasol, NBY, Physician, Inflammation, Patient, Food and Drug Administration, NovaBay Pharmaceuticals, Pain, FDA, Ophthalmology, Food, Pharmaceutical industry

EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S.

Key Points: 
  • EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S.
  • Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel.
  • Eyenovia acquired the U.S. commercial rights to clobetasol propionate ophthalmic suspension 0.05% from Formosa Pharmaceuticals in August 2023.
  • This co-promotion agreement reflects our shared commitment to bring scientifically developed, cutting-edge and high-quality ophthalmic products to physicians and the patients they treat.”

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

Retrieved on: 
Tuesday, March 12, 2024
Dermatology, Atopic dermatitis, Inflammation, JNJ, Research, American Academy, Cancer, FABP5, Skin, FABP, Pain, Epidermis, Oxidative stress, Pharmaceutical industry

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .

Key Points: 
  • SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .
  • Artelo was awarded the opportunity to present preclinical dermatology research on ART26.12 in San Diego, California, on March 11, 2024, concurrent with the American Academy of Dermatology Annual Meeting.
  • "We are pleased to have been selected to present our ART26.12 program to the J&J immuno-dermatology leadership team," said Dr. Andrew Yates, Chief Scientific Officer of Artelo.
  • “Our drug discovery program is investigating several oral, small molecule, FABP5 inhibitors,” said Professor Saoirse O'Sullivan, Vice President Translational Science of Artelo.

DHCS Kicks Off Mobile Dental Van Tour

Retrieved on: 
Friday, April 5, 2024
Children, Health, General Health, State, Local, Hispanic, Health Insurance, Family, Public Policy, Government, Consumer, Dental, Teens, Dental care, California Department, Dentistry, X-ray, Public health, Tooth decay, News, Overalls, Medi-Cal, DHCS, Pain, Crown, Multimedia

The California Department of Health Care Services (DHCS) today kicked off its second mobile dental van tour in Fresno.

Key Points: 
  • The California Department of Health Care Services (DHCS) today kicked off its second mobile dental van tour in Fresno.
  • Through the Smile California campaign, DHCS delivers preventive dental services to children and youth, enhancing utilization of essential dental care and improving oral health, particularly for underserved groups.
  • View the full release here: https://www.businesswire.com/news/home/20240404346598/en/
    Adrianna Alcala-Beshara, Chief of DHCS’ Medi-Cal Dental Division (Photo: Business Wire)
    “Medi-Cal Dental is committed to ensuring that millions of Californians have access to the dental care they need to keep their teeth and gums healthy and strong,” said Adrianna Alcala-Beshara, Chief of DHCS’ Medi-Cal Dental Division.
  • MEDI-CAL DENTAL SERVICES: With Medi-Cal, preventive dental services are covered at no cost.

Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales

Retrieved on: 
Thursday, April 4, 2024
Medical Devices, Health, Hospitals, Surgery, Physical Therapy, Biotechnology, Freedom, University, Growth, Medicine, Learning, Central Florida, Inc., Area, Patient, Medical device, IDE, Surgeon, ATEC, Spine, Pain

Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales.

Key Points: 
  • Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales.
  • Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years.
  • “The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology,” said Brian Snider, Chief Executive Officer at Spineology.
  • Prior to joining Spineology, Mr. Rooney spent nearly six years with Alphatec Spine (Nasdaq: ATEC), where he served as the Vice President of Sales, East.

FOX Nation to Debut New Docuseries ‘Surviving Hamas: A Benjamin Hall Special’ on April 9

Retrieved on: 
Thursday, April 4, 2024
Film & Motion Pictures, General Entertainment, Other Entertainment, Entertainment, TV and Radio, The Roku Channel, Hamas, Gen, Grief, Apple TV, DIRECTV, YouTube TV, Survival, Android TV, Fox News, FuboTV, Nir Oz, Google TV, Benjamin Hall, Amazon Fire TV, News, Leg, Roku, Survivor, Samsung, STEAM, Front, Xfinity, Generation Z, Pain, Fox Nation, IOS, Vizio, Android, Hall, Xbox One

FOX Nation will debut a two-part docuseries hosted by FOX News correspondent Benjamin Hall on April 9, announced Lauren Petterson, president of the platform.

Key Points: 
  • FOX Nation will debut a two-part docuseries hosted by FOX News correspondent Benjamin Hall on April 9, announced Lauren Petterson, president of the platform.
  • Entitled Surviving Hamas: A Benjamin Hall Special, the two hour-long episodes will explore the devastating firsthand experiences of individuals in the Israeli community following the October 7, 2023 attack.
  • Throughout the series, Hall visits some of the hardest hit communities providing an update for viewers as the 200-day milestone nears.
  • FOX Nation is a direct-to-consumer on-demand streaming service designed to complement the FOX News Channel experience with a members-only destination for its most passionate and loyal super fans.

Dr. Phil’s Merit Street Media™ Premiers to an Unprecedented 80+ Million Homes

Retrieved on: 
Tuesday, April 2, 2024
TV and Radio, General Entertainment, Entertainment, Health, Channel, Samsung Electronics, Saint, Apple TV, DIRECTV, Android TV, IPhone, Partnership, Grace, Smart, Free, News, Female, Interview, History, Politics, Parenting, Student, Amazon Fire TV, City, Roku, NASA, Samsung, Wireless, Dream, Pain, FAST, The Sundays, Android, DEI

Merit Street Media will begin in 20 million homes on Samsung Smart TVs – the first FAST platform to offer Dr. Phil content – and will continue to roll out to millions of additional user homes and devices over the coming months.

Key Points: 
  • Merit Street Media will begin in 20 million homes on Samsung Smart TVs – the first FAST platform to offer Dr. Phil content – and will continue to roll out to millions of additional user homes and devices over the coming months.
  • Merit+ can be downloaded on iPhone and Android mobile devices, Apple TV, Android TV, Fire TV, and Roku.
  • With its expansive reach and diverse distribution channels, Merit Street Media will bring its rich tapestry of original and acquired programming to viewers nationwide.
  • “The News on Merit Street” (Live, Weeknights 7-8 PM ET): Takes a comprehensive approach to the day's top headlines.